Categories: DevelopmentLED
Alesta Therapeutics pioneers innovative small molecule therapies targeting GCN2 kinase for rare neuro-related diseases and cancer.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.01.2025 | Series A | $66.94M | - |
Mentions in press and media 4
| Date | Title | Description |
| 10.01.2025 | Alesta Therapeutics: A New Dawn for Rare Disease Treatment | In the world of biotechnology, innovation is the lifeblood. Alesta Therapeutics, a rising star based in Leiden, Netherlands, has just secured €65 million in a Series A funding round. This significant investment is a beacon of hope for patie... |
| 08.01.2025 | Alesta Therapeutics: €65 Million (Series A) Raised To Develop Small Molecule Therapies For Rare Diseases | Alesta Therapeutics, a biotechnology company focused on developing transformative small molecule therapies for rare diseases, announced the closing of an oversubscribed €65 million Series A funding round. This funding round was co-led by Fr... |
| 08.01.2025 | Alesta Therapeutics Raises €65M in Series A Funding | Alesta Therapeutics, a Leiden, the Netherlands-based biotechnology company focused on developing transformative small molecule therapies for rare diseases, raised €65M in Series A funding.
The round was led by Frazier Life Sciences and Droi... |
| - | Alesta Therapeutics | “Alesta Therapeutics pioneers innovative small molecule therapies for rare diseases, including hypophosphatasia and Charcot-Marie-Tooth” |
Reviews 0
